Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 72.1%

Neg 0% Neu 0% Pos 72.1%

Guggenheim analyst Seamus Fernandez maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and raises the price target from $40 to $55.